AMAG wins FDA approval for Makena’s single-dose treatment for pregnant women
Makena is indicated to lower the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one preterm baby earlier. The
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties.
Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in
33A is an antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics’ newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding